Cas:27568-04-3 Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate manufacturer & supplier

Chemical Name:Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate

CAS.NO:27568-04-3

Synonyms:3-quinolinecarboxylic acid, 1,4-dihydro-8-methoxy-4-oxo-, ethyl ester;Ethyl 4-hydroxy-8-methoxy-3-quinolinecarboxylate;4-HYDROXY-8-METHOXY-QUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER;3-Quinolinecarboxylic acid, 4-hydroxy-8-methoxy-, ethyl ester;MFCD00173382;ethyl 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate;4-Hydroxy-8-methoxyquinoline-3-carboxylic acid ethyl ester;ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate

Molecular Formula:C₁₃H₁₃NO₄

Molecular Weight:247.247

HS Code:2933499090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:373.2±37.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.610

PSA:68.65000

Exact Mass:247.084457

LogP:3.64

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 3-quinolinecarboxylic acid, 1,4-dihydro-8-methoxy-4-oxo-, ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-quinolinecarboxylic acid, 1,4-dihydro-8-methoxy-4-oxo-, ethyl ester Use and application,4-HYDROXY-8-METHOXY-QUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER technical grade,usp/ep/jp grade.

Related News: In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate manufacturer The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate supplier Pharmaceutical intermediates and APIs belong to the fine chemical industry. Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate vendor The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. Ethyl 4-hydroxy-8-methoxyquinoline-3-carboxylate factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.